Meibography in clinical practice


Technological advances mean meibography may be used to diagnose MGD

Meibomian gland dysfunction (MGD) is one of the most common causes of an abnormality of the tear film lipid layer and evaporative dry eye.1–5 Numerous risk factors of MGD are reported (Table 1).6 Its prevalence varies between countries from 20% to 60%, with the highest rate in Japan.6 MGD is a chronic, diffuse abnormality of the meibomian glands, commonly characterized by terminal duct obstruction and/or qualitative/quantitative changes in the glandular secretion.7 This may result in alteration of the tear film, symptoms of eye irritation, clinically apparent inflammation and ocular surface disease.7

Meibography is the only clinically in vivo technique to visualize the morphology of the meibomian glands. When using this method, the structure of the meibomian glands, including the ducts and acini, can be observed.8–16 Meibography provides photographic documentation of the meibomian gland under specialized illumination techniques.17 This article is aimed to summarize recent development and investigation in meibography and its clinical relevance.

There are two principles in meibography. One is the transillumination of the everted lid11,18,19 the other is direct illumination, named the non-contact meibography.15,20–22 In the transillumination technique, the eyelid is everted over a light source.11,13,23 The most basic version uses white light, for example from a Finoff transilluminator. This is applied to the cutaneous side of the everted eyelid and allows observation from the palpebral conjunctival surface. Tapie24 was probably first describing evaluation of meibomian glands by transilluminating lids in 1977. He also captured the meibomian glands using infrared film (IR). Jester et al.16 adapted the biosmicroscopic and photographic techniques to improve upon Tapie's technique.16 Subsequently many other groups have used the transillumination IR techniques in meibomian gland observation.11,18,19,25

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.